Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006.
We describe the epidemiology of heterogeneously resistant Staphylococcus aureus (hVISA) identified in Canadian hospitals between 1995 and 2006. hVISA isolates were confirmed by the population analysis profiling-area under the curve method. Only 25 hVISA isolates (1.3% of all isolates) were detected. hVISA isolates were more likely to have been health care associated (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.9 to 14.2) and to have been recovered from patients hospitalized in central Canada (OR, 3.0; 95% CI, 1.2 to 7.4). There has been no evidence of vancomycin "MIC creep" in Canadian strains of methicillin (meticillin)-resistant S. aureus, and hVISA strains are currently uncommon.
Adam
Heather J
HJ
Department of Laboratory Medicine & Pathobiology, University of Toronto, and Hospital for Sick Children, Toronto, Ontario, Canada.
Louie
Lisa
L
Watt
Christine
C
Gravel
Denise
D
Bryce
Elizabeth
E
Loeb
Mark
M
Matlow
Anne
A
McGeer
Allison
A
Mulvey
Michael R
MR
Simor
Andrew E
AE
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002170:Canada / Q000453:epidemiology; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000502:physiology; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology; D014640:Vancomycin / Q000627:therapeutic use*; D020713:Vancomycin Resistance / Q000235:genetics*
D000900:Anti-Bacterial Agents; D014640:Vancomycin